HK Stock MarketDetailed Quotes
01558 HEC CJ PHARM
- 12.800
- +0.300+2.40%
Not Open Apr 26 16:08 CST
11.26BMarket Cap5.12P/E (TTM)
12.820High12.320Low1.99MVolume12.440Open12.500Pre Close25.24MTurnover0.30%Turnover Ratio5.12P/E (Static)879.97MShares13.04052wk High1.29P/B8.37BFloat Cap6.02052wk Low--Dividend TTM653.77MShs Float26.947Historical High--Dividend LFY4.00%Amplitude3.350Historical Low12.686Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
HEC CJ PHARM Key Stats
All
YOY
| (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | (Q6)Jun 30, 2021 | (Q3)Mar 31, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 68.08%6.29B | 148.12%3.21B | 309.83%3.74B | 539.47%1.29B | -61.08%913.79M | --449.54M | -90.29%202.25M | --102.36M | -62.27%2.35B | -32.15%2.08B |
| Operating income | 68.08%6.29B | 148.12%3.21B | 309.83%3.74B | 539.47%1.29B | -61.08%913.79M | -90.29%202.25M | -62.27%2.35B | -32.15%2.08B | ||
| Cost of sales | -45.61%-1.31B | -93.92%-645.07M | -109.00%-898.88M | -227.87%-332.65M | -22.34%-430.09M | ---- | 71.25%-101.46M | ---- | 61.86%-351.55M | 21.66%-352.86M |
| Operating expenses | -45.61%-1.31B | -93.92%-645.07M | -109.00%-898.88M | -227.87%-332.65M | -22.34%-430.09M | -199.05M | 71.25%-101.46M | -37.6M | 61.86%-351.55M | 21.66%-352.86M |
| Gross profit | 75.18%4.99B | 166.89%2.56B | 488.40%2.85B | 853.15%960.66M | -75.77%483.7M | -94.18%100.79M | -62.34%2B | -33.96%1.73B | ||
| Selling expenses | -27.17%-1.55B | -41.72%-755.5M | -133.21%-1.22B | -105.89%-533.11M | 54.79%-521.67M | ---- | 62.30%-258.93M | ---- | 51.13%-1.15B | 38.52%-686.86M |
| Administrative expenses | -13.96%-385.7M | -14.99%-172.11M | 5.57%-338.45M | 19.15%-149.67M | -12.68%-358.4M | ---- | -15.47%-185.12M | ---- | 36.82%-318.07M | 20.65%-160.32M |
| Research and development expenses | -48.35%-192.29M | -140.22%-98.26M | -18.18%-129.61M | 17.64%-40.91M | -18.63%-109.67M | ---- | 9.67%-49.67M | ---- | ---92.45M | ---54.98M |
| Impairment and provision | -265.88%-6.63M | -94.83%276K | 225.79%4M | 127.51%5.34M | -172.33%-3.18M | ---- | -475.56%-19.42M | ---- | 192.75%4.39M | -26.03%5.17M |
| -Other impairment is provision | -265.88%-6.63M | -94.83%276K | 225.79%4M | 127.51%5.34M | -172.33%-3.18M | ---- | -475.56%-19.42M | ---- | 192.75%4.39M | -26.03%5.17M |
| Special items of operating profit | 40.81%-499.8M | 1.05%-140.22M | -1,083.60%-844.35M | -150.56%-141.71M | -89.51%85.84M | ---- | -220.19%-56.56M | ---- | 1,917.47%818.08M | 191.38%47.06M |
| Operating profit | 633.24%2.35B | 1,289.63%1.4B | 175.84%321.07M | 121.46%100.61M | -133.74%-423.38M | -153.23%-468.91M | -49.28%1.25B | -29.92%880.9M | ||
| Financing cost | 19.26%-227.4M | 0.54%-136.27M | -15.52%-281.65M | -14.85%-137.01M | 0.16%-243.81M | ---- | 3.06%-119.3M | ---- | -19.41%-244.21M | -45.75%-123.06M |
| Share of profits of associates | ---29K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 5,294.88%2.13B | 3,566.44%1.26B | 105.91%39.42M | 93.81%-36.4M | -166.03%-667.18M | -177.62%-588.2M | -55.47%1.01B | -35.37%757.84M | ||
| Tax | -2,859.96%-270.95M | -6,138.81%-237.93M | -87.65%9.82M | -95.15%3.94M | 145.92%79.46M | ---- | 157.57%81.23M | ---- | 52.19%-173.02M | 33.59%-141.1M |
| After-tax profit from continuing operations | 3,669.02%1.86B | 3,254.22%1.02B | 108.38%49.24M | 93.60%-32.46M | -170.18%-587.72M | -182.20%-506.98M | -56.09%837.41M | -35.77%616.74M | ||
| Earning after tax | 3,669.02%1.86B | 3,254.22%1.02B | 108.38%49.24M | 93.60%-32.46M | -170.18%-587.72M | -182.20%-506.98M | -56.09%837.41M | -35.77%616.74M | ||
| Minority profit | -399.92%-136.8M | -1,758.04%-5.57M | -36,385.33%-27.36M | 558.82%336K | 96.33%-75K | ---- | 106.65%51K | ---- | 82.26%-2.04M | 90.71%-767K |
| Profit attributable to shareholders | 2,501.23%1.99B | 3,238.90%1.03B | 113.04%76.6M | 93.53%-32.8M | -170.00%-587.65M | -182.11%-507.03M | -56.25%839.46M | -36.24%617.51M | ||
| Basic earnings per share | 2,411.11%2.26 | 3,025.00%1.17 | 113.43%0.09 | 93.10%-0.04 | -170.53%-0.67 | -182.86%-0.58 | -56.02%0.95 | -35.78%0.7 | ||
| Diluted earnings per share | 2,411.11%2.26 | 3,025.00%1.17 | 113.43%0.09 | 93.10%-0.04 | -226.42%-0.67 | -192.06%-0.58 | -74.40%0.53 | -42.20%0.63 | ||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | CAS (2007) | IAS | CAS (2007) | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg